

Medical drug benefit *Clinical Criteria* updates

On September 19, 2019, the Pharmacy and Therapeutics (P&T) Committee approved the following *Clinical Criteria* applicable to the **medical drug benefit** for Anthem Blue Cross. These policies were developed, revised or reviewed to support clinical coding edits.

Visit [Clinical Criteria](#) to search for specific policies. For questions or additional information, use this [email](#).

Please see the explanation/definition for each category of *Clinical Criteria* below:

- New: newly published criteria
- Revised: addition or removal of medical necessity requirements, new document number
- Annual Review: minor wording and formatting updates, new document number
- Updates marked with an asterisk (*): Criteria may be perceived as more restrictive

Please share this notice with other members of your practice and office staff.

Please note: The *Clinical Criteria* listed below applies only to the medical drug benefits contained within the member's medical plan. This does not apply to pharmacy services.

Effective date	Document number	<i>Clinical Criteria</i> title	New, revised, annual review
February 27, 2020	ING-CC-0081	<i>Crysvita (burosumab-twza)</i>	Revised
February 27, 2020	ING-CC-0018	<i>Lumizyme (alglucosidase alfa)</i>	Reviewed
February 27, 2020	ING-CC-0021	<i>Fabrazyme (agalsidase beta)</i>	Revised
February 27, 2020	ING-CC-0002	<i>Zinplava (bezlotoxumab)</i>	Revised
February 27, 2020	ING-CC-0017	<i>Xiaflex (collagenase clostridium histolyticum)</i>	Revised
February 27, 2020	ING-CC-0013	<i>Mepsevii (vestronidase alfa)</i>	Revised
February 27, 2020	ING-CC-0022	<i>Vimizim (elosulfase alfa)</i>	Revised
February 27, 2020	ING-CC-0023	<i>Naglazyme (galsulfase)</i>	Revised
February 27, 2020	ING-CC-0024	<i>Elapraxe (idursulfase)</i>	Revised
February 27, 2020	ING-CC-0025	<i>Aldurazyme (laronidase)</i>	Revised
February 27, 2020	ING-CC-0007	<i>Synagis (palivizumab)*</i>	Revised
February 27, 2020	ING-CC-0012	<i>Brineura (cerliponase alfa)*</i>	Revised
February 27, 2020	ING-CC-0058	<i>Octreotide Agents (Sandostatin and Sandostatin LAR)</i>	Reviewed
February 27, 2020	ING-CC-0072	<i>Selective Vascular Endothelial Growth Factor (VEGF) Antagonists*</i>	Revised

<https://mediproviders.anthem.com/ca>

Anthem Blue Cross is the trade name of Blue Cross of California. Anthem Blue Cross and Blue Cross of California Partnership Plan, Inc. are independent licensees of the Blue Cross Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. Blue Cross of California is contracted with L.A. Care Health Plan to provide Medi-Cal Managed Care services in Los Angeles County. IngenioRx, Inc. is an independent company providing pharmacy benefit management services on behalf of Anthem Blue Cross.